Group 1 - The stock price of Wanbangde as of August 21, 2025, is 7.86 yuan, down 0.17 yuan from the previous trading day's closing price, representing a decline of 2.12% [1] - The company operates in the chemical pharmaceutical sector, with its main business segments being pharmaceutical manufacturing (48.76%), specialized equipment manufacturing and services (32.21%), and pharmaceutical distribution (15.41%) for the year 2024 [1] - Wanbangde announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., received an invention patent certificate from the National Intellectual Property Administration for a compound with specific disulfide bond structures, which could provide new drug candidates in various disease treatment areas [1] Group 2 - On August 21, 2025, the net outflow of main funds for Wanbangde was 23.04 million yuan, accounting for 0.53% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 62.20 million yuan, representing 1.43% of the circulating market value [1]

证券日报网讯 8月21日晚间，万邦德发布公告称，公司全资子公司万邦德制药集团有限公司近日收到国 家知识产权局的《发明专利证书》，发明名称：一种二硫环肽化合物及其制备方法和应用。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Wanbangde Pharmaceutical Holdings Group Co., Ltd. has received a patent for a new compound and its preparation method, which may enhance its competitive edge in the pharmaceutical industry [2] - Wanbangde's revenue composition for the year 2024 is as follows: 48.76% from pharmaceutical manufacturing, 32.21% from specialized equipment manufacturing and services, 15.41% from pharmaceutical distribution, and 3.62% from other industries [2]